ClinicalTrials.gg
RecruitingNCT07841977Updated Oct 27, 2026

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

A Phase 2 interventional study of Seladelpar and PTM Seladelpar in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Planned enrollment
5th of 10
132 · median 126
Started
2026
the only one that year
Phase 2
4 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 2, and was the 10th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC).

The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a diagnosis of primary biliary cholangitis (PBC) as defined by a history of any 2 of the following criteria:

    1. ALP above 1.0 × the for at least 6 months
    2. Positive antimitochondrial antibody titer (> 1:40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or positive PBC-specific antinuclear antibodies
    3. Documented liver results consistent with PBC
  • Used ursodeoxycholic acid (UDCA) for the past 12 months (stable dose for > 6 months prior to screening), or intolerant to UDCA (last dose of UDCA > 90 days prior to screening)
  • Have an ALP ≥ 1.67 × ULN at screening
  • Have a negative serum pregnancy test at screening

Key Exclusion Criteria:

  • Have other causes of liver disease including viral, alcoholic, , and metabolic associated steatohepatitis (MASH).
  • Cirrhosis with Score ≥ 7, corresponding to Class B or C. Individuals with compensated cirrhosis (ie, Child-Pugh Class A) are allowed if they meet all other criteria.
  • Have evidence of portal hypertension or hepatic decompensation (historic or current), including but not limited to: hepatic encephalopathy, known esophageal or gastric varices, history of liver transplantation, current placement on liver transplant list, Model for End Stage Liver Disease score ≥ 12, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome.
  • Have previous exposure to seladelpar or cilofexor
  • Used obeticholic acid, fenofibrate, bezafibrate, elafibranor, pemafibrate, or saroglitazar within 6 weeks (42 days, inclusive) of screening date
  • Require or expect to require treatment with ≥ 5 mg prednisone (or systemic equivalents) for > 2 weeks during the study
  • Are on any systemic drug for antipruritic treatment that has required a dose adjustment in the 30 days before screening, or initiated a systemic antipruritic drug in the 30 days before screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Seladelpar (SEL) 10 mg + Placebo-to-Match (PTM) Cilofexor (CILO) Dose A + CILO Dose B

    Participants will receive a dose of SEL 10 mg capsule along with PTM CILO Dose A tablets and CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an Active Treatment Extension (ATE) Period, during which they will receive SEL 10 mg along with either CILO Dose A or Dose B at the original randomized dose in a blinded fashion, up to Week 312.

    Drug: Seladelpar · Drug: Cilofexor Dose B · Drug: PTM Cilofexor Dose A

  • Experimental
    SEL 10 mg + CILO Dose A + PTM CILO Dose B

    Participants will receive a dose of SEL 10 mg capsule along with CILO Dose A tablets and PTM CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will receive SEL 10 mg along with either CILO Dose A or Dose B at the original randomized dose in a blinded fashion, up to Week 312.

    Drug: Seladelpar · Drug: PTM Cilofexor Dose B · Drug: Cilofexor Dose A

  • Active comparator
    SEL 10 mg + PTM CILO Dose A + PTM CILO Dose B

    Participants will receive a dose of SEL 10 mg capsule along with PTM CILO Dose A tablets and PTM CILO Dose B tablets, once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will initiate open-label SEL 10 mg and be re-randomized in a 1:1 ratio to receive CILO Dose A or Dose B in a blinded fashion, up to Week 312.

    Drug: Seladelpar · Drug: PTM Cilofexor Dose A · Drug: PTM Cilofexor Dose B

  • Placebo comparator
    PTM SEL 10 mg + PTM CILO Dose A + PTM CILO Dose B

    Participants will receive a dose of PTM SEL 10 mg capsule along with PTM CILO Dose A tablets and PTM CILO Dose B tablets once daily up to 24 weeks. At completion of Week 24, participants will continue in an ATE Period, during which they will initiate open-label SEL 10 mg and be re-randomized in a 1:1 ratio to receive CILO Dose A or Dose B in a blinded fashion, up to Week 312.

    Drug: PTM Seladelpar · Drug: PTM Cilofexor Dose A · Drug: PTM Cilofexor Dose B

Interventions

  • Capsule administered orally

  • DrugPTM Seladelpar

    Capsule administered orally

  • DrugCilofexor Dose B

    Tablet administered orally

  • DrugPTM Cilofexor Dose A

    Tablet administered orally

  • DrugPTM Cilofexor Dose B

    Tablet administered orally

  • DrugCilofexor Dose A

    Tablet administered orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Concentration of Alkaline Phosphate (ALP) at Week 24

    Time frame: Baseline, Week 24

  2. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Time frame: First dose up to 30 days post last dose (up to 318 weeks)

  3. Percentage of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: First dose up to 30 days post last dose (up to 318 weeks)

Secondary outcomes

  1. Proportion of Participants Achieving the Biochemistry Composite Endpoint at Week 24

    Defined as the percentage of participants with ALP \< 1.67 × upper limit of normal (ULN), ALP decrease of ≥ 15%, and total bilirubin ≤ 1 × ULN.

    Time frame: Week 24

  2. Proportion of Participants Achieving ALP Normalization at Week 24

    ALP Normalization is defined as ALP ≤ 1.0 × ULN.

    Time frame: Week 24

  3. Change From Baseline to Week 24 in Weekly Average Pruritus Numerical Rating Scale (NRS)

    Time frame: Baseline, Week 24

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's planned 26 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Dec 2028, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Dec 2028was Jun 2028
CompletionEst.
Jun 2034
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Peak Gastroenterology Associates · Colorado Springs, United States
  • Florida Research Institute · Lakewood Rch, United States
  • Digestive Healthcare of Georgia · Atlanta, United States
  • GI Associates of Northeast Tennessee · Johnson City, United States
Oct 27, 2026
Primary completion
Jun 2028→Dec 2028
Oct 27, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedHave a diagnosis of primary biliary cholangitis (PBC) as defined by a history of any 2 of the following criteria:
  • EditedRequire or expect to require treatment with ≥ 5 mg prednisone (or systemic equivalents) for > 2 weeks during the Blinded Treatment or ATE Periodsstudy
Oct 27, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 2 updates
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Peak Gastroenterology Associates · Colorado Springs, United States
    • Florida Research Institute · Lakewood Rch, United States
    • Digestive Healthcare of Georgia · Atlanta, United States
    • GI Associates of Northeast Tennessee · Johnson City, United States
    Primary completion Jun 2028→Dec 2028
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedHave a diagnosis of primary biliary cholangitis (PBC) as defined by a history of any 2 of the following criteria:
    • EditedRequire or expect to require treatment with ≥ 5 mg prednisone (or systemic equivalents) for > 2 weeks during the Blinded Treatment or ATE Periodsstudy
    + 2 other changes: verification date and references
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841977
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Oct 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2034 (estimated)
Last update
Oct 27, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion